Sanara MedTech Return on Equity

Sanara MedTech (SMTI) currently reports a ROE of -403.03%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore Sanara MedTech's ROE history and peer comparisons.

Sanara MedTech's ROE of -403.03% is lower than the Healthcare sector average of -75.84%. That is roughly 431.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sanara MedTech's current -403.03% should be judged against Healthcare norms (sector average: -75.84%) and against SMTI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -403.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Sanara MedTech, and consider following SMTI for alerts when major investors trade the stock.

Sanara MedTech is classified in the Healthcare sector. On ROE, it currently shows -403.03% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SMTI with unrelated industries.